Dicerna Pharma (NASDAQ: DRNA) reported Q1 EPS of ($0.68), $0.02 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $133 thousand versus the consensus estimate of $20 thousand.

Guidance

With the closing of its Preferred Stock transaction, Dicerna believes that it has sufficient cash to fund the execution of its current operating plan into 2019, which includes focusing its resources on advancing its first three development programs into proof of concept studies and a fourth program into formal preclinical development. This estimate assumes no additional funding from new partnership agreements or from additional financing events.

For earnings history and earnings-related data on Dicerna Pharma (DRNA) click here.